SciBase unveils growth strategy including plans for US launch of Nevisense

Following the Pre-Market Approval (PMA) of Nevisense in the US in June, SciBase today presents an update of their strategic growth plan. The focus of the plan is SciBase's entry into the US market, the continued growth in the core market Germany, and the utilization of the current product platform for additional clinical indications.The strategic plan has been developed together with the Company's Board and to support the above includes a reasonably aggressive investment strategy. It is the Board’s opinion that the current financial resources as of end-June of over 60MSEK, will be